Karur Vysya Bank Strong Provisional Financial Growth for Fiscal Year 2026

Karur Vysya Bank has announced its provisional financial performance for the fiscal year ending March 31, 2026. The bank recorded strong year-on-year growth, with total business reaching ₹2,14,409 crore. Advances saw a significant rise of 16.87%, while total deposits grew by 13.31%. These results underscore the bank’s sustained momentum heading into the new fiscal year, highlighting robust expansion across core business segments despite the competitive banking landscape.

Year-End Financial Highlights

Karur Vysya Bank’s provisional data for the year ended March 31, 2026, reflects a period of consistent expansion. Total business surpassed the ₹2 lakh crore mark, settling at ₹2,14,409 crore, which represents a healthy 14.92% growth compared to the previous fiscal year. This upward trajectory is supported by double-digit growth in both lending and deposit-gathering activities.

Breakdown of Key Segments

The bank’s credit growth remains a primary driver of performance, with advances climbing to ₹98,743 crore, marking an impressive 16.87% increase year-on-year. On the liability side, total deposits grew by 13.31% to reach ₹1,15,666 crore. Excluding certificate of deposits, the core deposit base reached ₹1,09,868 crore, showing a 12.33% year-on-year improvement. Meanwhile, the CASA (Current Account Savings Account) ratio stood at ₹31,122 crore for the period.

Quarterly Performance Context

When analyzing the final quarter (Q4) ending March 31, 2026, against the preceding quarter (Q3) ending December 31, 2025, the bank maintained steady growth. Total business expanded by 1.31%, while advances saw a quarterly uptick of 1.74%. Total deposits (excluding certificate of deposits) demonstrated strong quarterly momentum with a 2.66% growth, signaling stable liquidity and deposit acquisition strategies as the bank closes the 2025-26 financial year.

Source: BSE

Previous Article

The New India Assurance Company Ltd Favorable Order Leads to Penalty Reversal

Next Article

Glenmark Pharmaceuticals Strategic Shift to Direct Commercialization of RYALTRIS in the U.S.